{"protocolSection":{"identificationModule":{"nctId":"NCT02228863","orgStudyIdInfo":{"id":"NRC-2014-01-005"},"organization":{"fullName":"National Rehabilitation Center, Seoul, Korea","class":"OTHER_GOV"},"briefTitle":"Upper Extremity Rehabilitation Using Robot and Botulinum Toxin"},"statusModule":{"statusVerifiedDate":"2014-08","overallStatus":"UNKNOWN","lastKnownStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-03"},"primaryCompletionDateStruct":{"date":"2017-02","type":"ESTIMATED"},"studyFirstSubmitDate":"2014-08-23","studyFirstSubmitQcDate":"2014-08-27","studyFirstPostDateStruct":{"date":"2014-08-29","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-08-27","lastUpdatePostDateStruct":{"date":"2014-08-29","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Joon-Ho Shin","investigatorTitle":"Team manager","investigatorAffiliation":"National Rehabilitation Center, Seoul, Korea"},"leadSponsor":{"name":"National Rehabilitation Center, Seoul, Korea","class":"OTHER_GOV"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"Concomitant use of botulinum toxin and robot would make better results regarding upper extremity function compared to robot, botulinum toxin, or no intervention."},"conditionsModule":{"conditions":["Stroke","Spasticity"],"keywords":["Stroke","Spasticity"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":348,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Early Inmotion and Botox","type":"EXPERIMENTAL","description":"Concomitant use of Inmotion and botulinum toxin from the baseline","interventionNames":["Other: Early Inmotion and Botox"]},{"label":"Botox, then Inmotion","type":"ACTIVE_COMPARATOR","description":"Inmotion training 4 weeks after botulinum toxin injection","interventionNames":["Other: Botox, then Inmotion"]},{"label":"Inmotion, then Botox","type":"ACTIVE_COMPARATOR","description":"From the baseline Inmotion, then Botox injection at 4 weeks after baseline","interventionNames":["Other: Inmotion, then Botox"]},{"label":"Late Inmotion and Botox","type":"ACTIVE_COMPARATOR","description":"No intervention, then Inmotion and Botox injection at 4 weeks from the baseline","interventionNames":["Other: Late Inmotion and Botox"]}],"interventions":[{"type":"OTHER","name":"Early Inmotion and Botox","description":"Concomitant use of Inmotion and Botox from the baseline","armGroupLabels":["Early Inmotion and Botox"]},{"type":"OTHER","name":"Botox, then Inmotion","description":"At baseline Botox injection and 4 weeks after Inmotion","armGroupLabels":["Botox, then Inmotion"]},{"type":"OTHER","name":"Inmotion, then Botox","description":"Inmotion from the baseline, then Botox injection at 4 weeks after baseline","armGroupLabels":["Inmotion, then Botox"]},{"type":"OTHER","name":"Late Inmotion and Botox","description":"No intervention until 4 weeks from the baseline. Then Inmotion and Botox injection","armGroupLabels":["Late Inmotion and Botox"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change of Fugl-Meyer Assessment","timeFrame":"Fugl-Meyer Assessment change from baseline at 8 weeks"}],"secondaryOutcomes":[{"measure":"Kinematic data","description":"Kinematic data from motion analysis (Vicon) Kinematic data from Inmotion","timeFrame":"Baseline, 4 weeks from baseline, 8 weeks from baseline, 12 weeks from baseline"},{"measure":"Spasticity of elbow and shoulder joint","description":"Modified Ashworth scale of elbow and shoulder joint Modified Tardieu scale of elbow and shoulder joint","timeFrame":"baseline, 4 weeks after baseline, 8 weeks after baseline, 12 weeks after baseline"},{"measure":"Medical research council scale of elbow and shoulder joint strength","timeFrame":"baseline, 4 weeks after baseline, 8 weeks after baseline, 12 weeks after baseline"},{"measure":"Painless range of motion of elbow and shoulder joint","timeFrame":"baseline, 4 weeks after baseline, 8 weeks after baseline, 12 weeks after baseline"},{"measure":"numeric rating scale of pain of elbow and shoulder joint","timeFrame":"baseline, 4 weeks after baseline, 8 weeks after baseline, 12 weeks after baseline"},{"measure":"Associated reaction rating scale","timeFrame":"baseline, 4 weeks after baseline, 8 weeks after baseline, 12 weeks after baseline"},{"measure":"surface electromyography data from bilateral upper extremities","timeFrame":"baseline, 4 weeks after baseline, 8 weeks after baseline, 12 weeks after baseline"},{"measure":"Behavioral activation system/behavioral inhition system scale","description":"In terms of motivation","timeFrame":"baseline, 4 weeks after baseline, 8 weeks after baseline, 12 weeks after baseline"},{"measure":"Controlled Oral Word Association Test","description":"Controlled Oral Word Association Test during baseline, 5 days of Inmotion, 20 days of Inmotion.\n\nThe test was done at rest and with Inmotion trial","timeFrame":"baseline, 5ays of Inmotion, 20 days of Inmotion"},{"measure":"Fugl-Meyer Assessment","timeFrame":"Baseline, 4 weeks from baseline, 8 weeks from baseline, 12 weeks from baseline"},{"measure":"Stroke impact scale","timeFrame":"baseline, 4 weeks after baseline, 8 weeks after baseline, 12 weeks after baseline"},{"measure":"Beck's depression index","timeFrame":"baseline, 4 weeks, 8 weeks, and 12 weeks from baseline"},{"measure":"Satisfaction about the intervention","timeFrame":"baseline, 4 weeks after baseline, 8 weeks after baseline, 12 weeks after baseline"},{"measure":"Adverse event","timeFrame":"From baseline to 12 weeks from the baseline"},{"measure":"Digit span test","description":"Digit span test(forward, backward) during baseline, 5 days of Inmotion, 20 days of Inmotion.\n\nThe test was done at rest and with Inmotion trial","timeFrame":"baseline, 5days after Inmotion, 20 days after Inmotion."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Hemiplegic patients secondary to first cerebrovascular accidents\n* Shoulder or Elbow flexor spasticity above or modified ashworth scale 1+\n* Cognitively intact enough to understand and follow the instructions from the investigator\n\nExclusion Criteria:\n\n* History of surgery of affected upper limb\n* Fracture of affected upper limb\n* Recent history of botulinum toxin injection within 6 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Joon-Ho Shin, MS","role":"CONTACT","phone":"82-2-901-1884","email":"asfreelyas@gmail.com"}],"overallOfficials":[{"name":"Joon-Ho Shin, MS","affiliation":"National Rehabilitation Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"National Rehabilitation Center","status":"RECRUITING","city":"Seoul","zip":"142884","country":"Korea, Republic of","contacts":[{"name":"Joon-Ho Shin, MS","role":"CONTACT","phone":"82-901-1884","email":"asfreelyas@gmail.com"},{"name":"Joon-Ho Shin, MS","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":37.566,"lon":126.9784}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Site of the present study","url":"http://nrc.go.kr"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"}],"ancestors":[{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spasticity","relevance":"HIGH"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000019274","term":"Botulinum Toxins, Type A"},{"id":"C000542869","term":"abobotulinumtoxinA"}],"ancestors":[{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","relevance":"LOW"},{"id":"M250157","name":"abobotulinumtoxinA","asFound":"Cross-","relevance":"HIGH"},{"id":"M20947","name":"Botulinum Toxins, Type A","asFound":"Cross-","relevance":"HIGH"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":false}